Literature DB >> 28433076

Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms.

Lu Wang1, Klaus J Busam2, Ryma Benayed2, Robert Cimera2, Jiajing Wang2, Ryan Denley2, Mamta Rao2, Ruth Aryeequaye2, Kerry Mullaney2, Long Cao2, Marc Ladanyi3, Meera Hameed2.   

Abstract

Spitzoid neoplasms are a distinct group of melanocytic tumors. Genetically, they lack mutations in common melanoma-associated oncogenes. Recent studies have shown that spitzoid tumors may contain a variety of kinase fusions, including ROS1, NTRK1, ALK, BRAF, and RET fusions. We report herein the discovery of recurrent NTRK3 gene rearrangements in childhood melanocytic neoplasms with spitzoid and/or atypical features, based on genome-wide copy number analysis by single-nucleotide polymorphism array, which showed intragenic copy number changes in NTRK3. Break-apart fluorescence in situ hybridization confirmed the presence of NTRK3 rearrangement, and a novel MYO5A-NTRK3 transcript, representing an in-frame fusion of MYO5A exon 32 to NTRK3 exon 12, was identified using a rapid amplification of cDNA ends-based anchored multiplex PCR assay followed by next-generation sequencing. The predicted MYO5A-NTRK3 fusion protein consists of several N-terminal coiled-coil protein dimerization motifs encoded by MYO5A and C-terminal tyrosine kinase domain encoded by NTRK3, which is consistent with the prototypical structure of TRK oncogenic fusions. Our study also demonstrates how array-based copy number analysis can be useful in discovering gene fusions associated with unbalanced genomic aberrations flanking the fusion points. Our findings add another potentially targetable kinase fusion to the list of oncogenic fusions in melanocytic tumors.
Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28433076      PMCID: PMC5417047          DOI: 10.1016/j.jmoldx.2016.11.005

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  37 in total

1.  The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.

Authors:  D H Wai; S R Knezevich; T Lucas; B Jansen; R J Kay; P H Sorensen
Journal:  Oncogene       Date:  2000-02-17       Impact factor: 9.867

2.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

3.  PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.

Authors:  Tatsuya Ozawa; Cameron W Brennan; Lu Wang; Massimo Squatrito; Takashi Sasayama; Mitsutoshi Nakada; Jason T Huse; Alicia Pedraza; Satoshi Utsuki; Yoshie Yasui; Adesh Tandon; Elena I Fomchenko; Hidehiro Oka; Ross L Levine; Kiyotaka Fujii; Marc Ladanyi; Eric C Holland
Journal:  Genes Dev       Date:  2010-10-01       Impact factor: 11.361

4.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

Authors:  David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister
Journal:  Nat Genet       Date:  2013-06-30       Impact factor: 38.330

5.  The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution.

Authors:  Mathew W Ludgate; Douglas R Fullen; Julia Lee; Lori Lowe; Carol Bradford; James Geiger; Jennifer Schwartz; Timothy M Johnson
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

6.  Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.

Authors:  B P Rubin; C J Chen; T W Morgan; S Xiao; H E Grier; H P Kozakewich; A R Perez-Atayde; J A Fletcher
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

7.  Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia.

Authors:  Johanna M Kralik; Wolfgang Kranewitter; Hans Boesmueller; Renate Marschon; Gertraud Tschurtschenthaler; Holger Rumpold; Kurt Wiesinger; Martin Erdel; Andreas L Petzer; Gerald Webersinke
Journal:  Diagn Pathol       Date:  2011-03-15       Impact factor: 2.644

8.  The genomic landscape of childhood and adolescent melanoma.

Authors:  Charles Lu; Jinghui Zhang; Panduka Nagahawatte; John Easton; Seungjae Lee; Zhifa Liu; Li Ding; Matthew A Wyczalkowski; Marcus Valentine; Fariba Navid; Heather Mulder; Ruth G Tatevossian; James Dalton; James Davenport; Zhirong Yin; Michael Edmonson; Michael Rusch; Gang Wu; Yongjin Li; Matthew Parker; Erin Hedlund; Sheila Shurtleff; Susana Raimondi; Vadodaria Bhavin; Yergeau Donald; Elaine R Mardis; Richard K Wilson; William E Evans; David W Ellison; Stanley Pounds; Michael Dyer; James R Downing; Alberto Pappo; Armita Bahrami
Journal:  J Invest Dermatol       Date:  2014-09-30       Impact factor: 8.551

9.  Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Authors:  A Vaishnavi; M Capelletti; P A Jänne; R C Doebele; A T Le; S Kako; M Butaney; D Ercan; S Mahale; K D Davies; D L Aisner; A B Pilling; E M Berge; J Kim; H Sasaki; S Park; G Kryukov; L A Garraway; Peter S Hammerman; J Haas; S W Andrews; D Lipson; P J Stephens; V A Miller; M Varella-Garcia
Journal:  Nat Med       Date:  2013-10-27       Impact factor: 53.440

10.  What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

Authors:  A Drilon; G Li; S Dogan; M Gounder; R Shen; M Arcila; L Wang; D M Hyman; J Hechtman; G Wei; N R Cam; J Christiansen; D Luo; E C Maneval; T Bauer; M Patel; S V Liu; S H I Ou; A Farago; A Shaw; R F Shoemaker; J Lim; Z Hornby; P Multani; M Ladanyi; M Berger; N Katabi; R Ghossein; A L Ho
Journal:  Ann Oncol       Date:  2016-02-15       Impact factor: 32.976

View more
  10 in total

Review 1.  Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms.

Authors:  James P Solomon; Jaclyn F Hechtman
Journal:  Cancer Res       Date:  2019-06-13       Impact factor: 12.701

Review 2.  The Morpho-Molecular Landscape of Spitz Neoplasms.

Authors:  Carlo Alberto Dal Pozzo; Rocco Cappellesso
Journal:  Int J Mol Sci       Date:  2022-04-11       Impact factor: 6.208

Review 3.  TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Authors:  Shivaani Kummar; Ulrik N Lassen
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

4.  Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.

Authors:  Monika A Davare; Jacob J Henderson; Anupriya Agarwal; Jacob P Wagner; Sudarshan R Iyer; Nameeta Shah; Randy Woltjer; Romel Somwar; Stephen W Gilheeney; Ana DeCarvalo; Tom Mikkelson; Erwin G Van Meir; Marc Ladanyi; Brian J Druker
Journal:  Clin Cancer Res       Date:  2018-08-31       Impact factor: 12.531

5.  Colonic Adenocarcinomas Harboring NTRK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 16 Cases and Review of the Literature.

Authors:  Jerzy Lasota; Małgorzata Chłopek; Jennifer Lamoureux; Jason Christiansen; Artur Kowalik; Bartosz Wasąg; Anna Felisiak-Gołąbek; Abbas Agaimy; Wojciech Biernat; Vincenzo Canzonieri; Giovanni Centonze; Ewa Chmielik; Ondrej Daum; Magdalena Dubová; Ireneusz Dziuba; Sebastian Goertz; Stanisław Góźdź; Anna Guttmejer-Nasierowska; Caj Haglund; Agnieszka Hałoń; Arndt Hartmann; Shingo Inaguma; Ewa Iżycka-Świeszewska; Maciej Kaczorowski; Paweł Kita; Małgorzata Kołos; Janusz Kopczyński; Michal Michal; Massimo Milione; Krzysztof Okoń; Rafał Pęksa; Michał Pyzlak; Ari Ristimäki; Janusz Ryś; Blażej Szostak; Joanna Szpor; Justyna Szumiło; Leszek Teresiński; Piotr Waloszczyk; Jarosław Wejman; Wojciech Wesołowski; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2020-02       Impact factor: 6.298

Review 6.  Identifying patients with NTRK fusion cancer.

Authors:  J P Solomon; R Benayed; J F Hechtman; M Ladanyi
Journal:  Ann Oncol       Date:  2019-11-01       Impact factor: 32.976

Review 7.  Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.

Authors:  Susan J Hsiao; Ahmet Zehir; Anthony N Sireci; Dara L Aisner
Journal:  J Mol Diagn       Date:  2019-05-07       Impact factor: 5.568

Review 8.  NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies.

Authors:  Antonio Marchetti; Benedetta Ferro; Maria Paola Pasciuto; Claudia Zampacorta; Fiamma Buttitta; Emanuela D'Angelo
Journal:  Pathologica       Date:  2022-06

9.  BRAF fusions identified in melanomas have variable treatment responses and phenotypes.

Authors:  Jacqueline A Turner; Judson G T Bemis; Stacey M Bagby; Anna Capasso; Betelehem W Yacob; Tugs-Saikhan Chimed; Robert Van Gulick; Hannah Lee; Richard Tobin; John J Tentler; Todd Pitts; Martin McCarter; William A Robinson; Kasey L Couts
Journal:  Oncogene       Date:  2018-09-25       Impact factor: 8.756

10.  Spitz melanoma is a distinct subset of spitzoid melanoma.

Authors:  Shyam S Raghavan; Sandra Peternel; Thaddeus W Mully; Jeffrey P North; Laura B Pincus; Philip E LeBoit; Timothy H McCalmont; Boris C Bastian; Iwei Yeh
Journal:  Mod Pathol       Date:  2020-01-03       Impact factor: 7.842

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.